---
id: eso-ich-2024
title: "ESO 2024 Guideline: Management of Spontaneous Intracerebral Hemorrhage"
short_title: "ESO ICH 2024"

organization: European Stroke Organisation
collaborators: null
country: Global (Europe-led)
url: https://eso-stroke.org/guidelines/
doi: null
pmid: null
open_access: true

specialty: neurology
guideline_type: clinical-practice
evidence_system: ESO GRADE
conditions:
  - intracerebral hemorrhage
  - ICH
  - hemorrhagic stroke
tags:
  - blood pressure management
  - reversal agents
  - neurosurgery
  - anticoagulant-associated ICH
  - hematoma expansion

publication_date: 2024-02-01
previous_version_date: 2021-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 European Stroke Organisation guideline update on the acute management of spontaneous intracerebral hemorrhage (ICH).

## Key Recommendations

### Initial Stabilization
- Airway, breathing, circulation.
- ICU-level monitoring for patients with altered consciousness or large hemorrhage.

### Blood Pressure Management
- **Acute lowering**: Target SBP â‰¤140 mmHg (and >110 mmHg) within 1 hour of presentation is recommended for patients presenting with SBP 150-220 mmHg.
- Avoid rapid or excessive BP lowering; maintain stable target.

### Reversal of Anticoagulation

#### Vitamin K Antagonist (VKA)-Associated ICH
- **4-Factor PCC** (25-50 units/kg): First-line for rapid INR reversal.
- **Vitamin K 10 mg IV**: Administer concurrently for sustained reversal.
- Target INR <1.3-1.5.

#### DOAC-Associated ICH
- **Dabigatran**: Idarucizumab 5 g IV.
- **Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)**: Andexanet alfa if available. 4F-PCC (50 units/kg) if andexanet unavailable.

#### Antiplatelet-Associated ICH
- Platelet transfusion NOT routinely recommended (may cause harm in some studies).
- Desmopressin (DDAVP) may be considered.

### Hemostatic Therapy
- Tranexamic acid: May reduce hematoma expansion but has not shown improved functional outcomes; can be considered in select cases.

### Surgical Intervention
- **Cerebellar Hemorrhage (>3 cm or with brainstem compression/hydrocephalus)**: Surgical evacuation is life-saving.
- **Supratentorial ICH**: Minimally invasive surgery (with or without thrombolysis) may be considered for moderate-to-large hemorrhages; open craniotomy not routinely beneficial for most patients.
- **Ventricular Drainage (EVD)**: For hydrocephalus secondary to intraventricular hemorrhage.

### Secondary Prevention
- Identify and treat underlying etiology (hypertension, CAA, vascular malformation).
- Cautious approach to resuming antithrombotic therapy; individualize based on thromboembolic vs. recurrent ICH risk.
